Digoxin

Introduction Overview

Generic Name

digoxin

Brand Name

Digitek, Digox, Lanoxin, Lanoxicaps, Cardoxin

Dosage Form

oral tablet, oral capsule, oral solution, injectable solution

Drug Class

Group V antiarrhythmics, Inotropic agents

Pharmacokinetics

Absorption:
Digoxin is well absorbed from the gastrointestinal tract after oral administration. Bioavailability varies depending on the formulation used, with tablets having an approximate bioavailability of 60-80%, capsules slightly higher, and the oral solution providing close to 100% bioavailability. Absorption rates can be influenced by factors such as gastrointestinal pH and motility, which may affect plasma concentrations and therapeutic response. Peak plasma levels are typically reached within 1 to 4 hours post oral administration, while intravenous administration results in immediate availability. Food intake does not significantly alter digoxin absorption, although certain gastrointestinal diseases may influence its uptake. Clinical implications include the need to maintain consistent dosing relationships with respect to meals and gastrointestinal conditions to ensure stable plasma levels.

Distribution:
Digoxin exhibits a large volume of distribution, approximately 6 to 7 L/kg, reflecting its extensive tissue binding, particularly in cardiac tissue, skeletal muscle, liver, and kidneys. It binds moderately to plasma proteins (about 25%) and rapidly penetrates tissue compartments. The drug's accumulation is notable in cardiac tissues, which contributes to its pharmacodynamic effects and toxicity profile. Distribution is also influenced by body composition, with lean body mass being a better predictor for dosing than total body weight. Digoxin crosses the placenta and is excreted into breast milk, necessitating caution in pregnancy and lactation. The tissue binding also contributes to the drug’s long half-life and slow decline in plasma concentrations after dosing cessation.

Metabolism:
Digoxin undergoes minimal hepatic metabolism; approximately 16% is metabolized primarily via reduction and conjugation pathways in the liver and gut flora transformation. The majority of circulating digoxin remains unchanged. Enterohepatic recycling is minimal, but variability in gut flora may influence metabolism to some degree. Clinically, since hepatic metabolism is limited, hepatic impairment typically does not necessitate major dose adjustments, though careful monitoring is still recommended.

Elimination:
Digoxin is predominantly eliminated unchanged via renal excretion, accounting for about 50-70% of the administered dose in patients with normal renal function. It is filtered at the glomerulus and secreted by the proximal renal tubules. The elimination half-life in patients with normal renal function averages 36 to 48 hours but can be significantly prolonged in those with renal impairment, necessitating dose reduction and careful plasma level monitoring to avoid toxicity. Non-renal elimination pathways are minor but become more relevant in renal dysfunction. The steady state is typically achieved within 5 to 7 days with regular dosing. The drug’s narrow therapeutic index combined with its renal clearance profile mandates frequent monitoring of renal function and digoxin serum levels in clinical practice.

Dosage Forms

Available Dosage Forms:
Digoxin is available in several oral and parenteral formulations to suit diverse clinical needs. Oral formulations include tablets, capsules, and oral solution (elixir). Injectable forms are available for intravenous or intramuscular use, primarily used when rapid digitalization is required or when oral administration is not feasible. Specific available dosage forms include:
- Oral tablets (Lanoxin, Digitek): 62.5 mcg, 125 mcg, 187.5 mcg, 250 mcg
- Oral capsules (Lanoxicaps): 62.5 mcg, 125 mcg, 187.5 mcg, 250 mcg
- Oral solution (elixir): concentration commonly at 0.05 mg/mL
- Injectable solution: typically 0.25 mg/mL

Dosages for Adults and Adolescents:
Adult dosing varies depending on the indication (heart failure or atrial fibrillation) and clinical status. For rapid digitalization in congestive heart failure, loading doses aim to establish 8 to 12 mcg/kg body weight in total; administered in divided doses, typically half as an initial dose followed by additional doses at 6-8 hour intervals, with clinical monitoring before further doses. Maintenance doses range from 125 to 500 mcg once daily based on age, renal function, and body weight. For atrial fibrillation, doses may be higher to achieve adequate ventricular rate control, but must be titrated carefully to minimize toxicity. Oral tablets and capsules typically have initial doses of 400-750 mcg, while injectable preparations allow rapid onset (5-30 minutes).

Specific Patient Populations:
Pediatric dosing is weight-based and age-specific. Loading (digitalizing) doses and maintenance doses are carefully titrated according to lean body weight with subdivided fractioned dosing to avoid toxicity. Premature infants have lower doses than full-term neonates. Dosage in infants and children ranges broadly (loading: 15-60 mcg/kg IV or orally in fractions; maintenance: 2-15 mcg/kg daily), adjusting for age and clinical response. Parenteral administration is reserved for urgent situations or when oral dosing is not possible. In elderly patients and those with impaired renal function, dose adjustments are necessary due to decreased clearance and increased risk of accumulation. Close monitoring of serum digoxin concentrations and renal function guides dosing modifications.

Mechanism Of Action

Digoxin exerts its primary pharmacological effect by inhibiting the enzyme Na+/K+-ATPase located on the membranes of cardiac myocytes. This inhibition leads to an increase in intracellular sodium concentration. Elevated intracellular sodium reduces the activity of the sodium-calcium exchanger, resulting in an accumulation of intracellular calcium ions. The increased intracellular calcium availability facilitates enhanced contractile force by promoting more effective actin-myosin interactions, thereby exerting a positive inotropic effect which strengthens cardiac muscle contractions.

In addition to its inotropic effects, digoxin influences cardiac electrophysiology. By increasing vagal (parasympathetic) tone and decreasing sympathetic outflow, digoxin reduces conduction velocity through the atrioventricular (AV) node and prolongs AV nodal refractory periods. This results in a decreased ventricular response rate in atrial fibrillation and atrial flutter, making digoxin effective as a rate-control agent in supraventricular tachyarrhythmias.

At the cellular signaling level, digoxin’s inhibition of Na+/K+-ATPase also impacts neurohormonal pathways implicated in heart failure. It counteracts elevated sympathetic nervous system activity and attenuates renin-angiotensin-aldosterone system activation, which collectively contribute to modulation of cardiac remodeling and neurohormonal balance. These mechanisms are crucial in the clinical benefits observed during management of congestive heart failure.

Clinically, digoxin’s dual action—improving cardiac contractility while controlling heart rate—makes it uniquely beneficial in patients with heart failure accompanied by atrial fibrillation. Compared to other inotropes, digoxin’s effect is more sustained given its tissue binding and long half-life, and its vagomimetic effects provide additional antiarrhythmic benefits. Multiple clinical trials have confirmed digoxin’s ability to improve symptoms and reduce hospitalizations in heart failure, albeit with careful adjustment to avoid toxicity due to its narrow therapeutic window.

Pharmacological Actions

Positive inotropic effect by increasing myocardial contractility through Na+/K+-ATPase inhibition
Negative chronotropic effect by enhancing vagal tone to reduce heart rate
Negative dromotropic effect by slowing conduction velocity through the atrioventricular node
Modulation of neurohormonal activation (sympathetic and renin-angiotensin systems) in heart failure
Reduction of ventricular response rate in atrial fibrillation and atrial flutter
Improvement of cardiac output in congestive heart failure
Antiarrhythmic properties via vagal effects and AV nodal conduction delay
Prolongation of refractory period in AV node contributing to rate control
Minimal direct effect on sinoatrial node automaticity
Increased stroke volume and decreased central venous pressure in heart failure

Therapeutic Or Clinical Uses

Management of congestive heart failure with reduced ejection fraction to improve symptoms and exercise tolerance
Control of ventricular rate in patients with atrial fibrillation and atrial flutter
Treatment of supraventricular arrhythmias, particularly atrial fibrillation with rapid ventricular response
Used in combination with other heart failure therapies for optimized clinical outcomes
Management of paroxysmal atrial tachycardias in select patients
Adjunctive therapy for chronic heart failure to reduce hospitalizations
Off-label use in some cases of junctional tachycardia
Reduction of heart failure symptoms particularly when beta blockers are contraindicated or not tolerated
Use in pediatric patients with heart failure or arrhythmias with appropriate dosing adjustments
Supportive therapy in heart failure with reduced renal function with dose modifications

Side Or Adverse Effects

Nausea, vomiting, and diarrhea often indicating early signs of toxicity
Anorexia and loss of appetite
Blurry or yellow vision (xanthopsia), visual disturbances including halos
Fatigue, dizziness, and headache
Confusion, disorientation, and neuropsychiatric symptoms including hallucinations
Cardiac arrhythmias including bradycardia, heart block, ventricular tachycardia, and ectopic beats
Palpitations and irregular heartbeat
Depression and anxiety symptoms
Rash or hypersensitivity reactions
Breast swelling or tenderness, particularly in male patients
Electrolyte imbalances exacerbated by digoxin toxicity, especially hypokalemia
Increased risk of toxicity with renal impairment or interacting drugs
Serious allergic reactions including angioedema or anaphylaxis (rare)
Symptoms of overdose which may be life-threatening, such as severe bradycardia or ventricular fibrillation
Gastrointestinal discomfort and abdominal pain

Precautions

Use cautiously in patients with pre-existing AV block or sick sinus syndrome without pacemaker
Careful monitoring required in patients with impaired renal function due to decreased clearance
Close monitoring in elderly patients who are more susceptible to toxicity
Avoid abrupt discontinuation to prevent exacerbation of heart failure
Monitor electrolyte levels carefully, particularly potassium, magnesium, and calcium
Caution in patients with thyroid dysfunction as hypothyroidism or hyperthyroidism can alter digoxin effects
Dose adjustments necessary in pediatric and geriatric populations
Careful use during pregnancy only if benefits outweigh risks, with fetal monitoring
Caution advised while breastfeeding due to uncertain effects on infant
Avoid dehydration and electrolyte imbalance which increase risk for digoxin toxicity
Monitor plasma digoxin concentrations periodically to maintain therapeutic levels
Use caution in patients with Wolff-Parkinson-White syndrome due to risk of arrhythmias
Regular cardiac monitoring recommended for detection of arrhythmias
Avoid use in patients with ventricular fibrillation
Use in combinations with other cardiotropic drugs requires careful interaction assessment

Warnings

Contraindicated in ventricular fibrillation due to risk of worsening arrhythmia
Narrow therapeutic index mandates careful dosing and monitoring to prevent fatal toxicity
Risk of digoxin toxicity increased by electrolyte abnormalities such as hypokalemia, hypomagnesemia
Levels above therapeutic range can cause life-threatening arrhythmias and cardiac arrest
Overdose symptoms include severe nausea, vomiting, vision changes, confusion, and irregular heartbeat
Avoid use in patients with hypersensitivity to digoxin or digitalis derivatives
Use caution during acute renal impairment or failure which reduces clearance significantly
Drug interactions may elevate digoxin levels leading to overdose risk
Warning for use in pregnancy due to potential fetal risks and maternal complications
Potential for neurotoxicity manifested by confusion and hallucinations, especially in elderly
Avoid use in patients with sick sinus syndrome without pacemaker due to risk of severe bradycardia
Abrupt withdrawal may exacerbate underlying cardiac conditions leading to decompensation
Careful dosing required in children due to variable pharmacokinetics and sensitivity
Risk of heart block or conduction disturbances especially if combined with other AV nodal blocking agents
Monitor for signs of allergic reactions or severe hypersensitivity

Contraindication

Known hypersensitivity or allergy to digoxin or digitalis glycosides
Ventricular fibrillation as digoxin may exacerbate this lethal arrhythmia
Concomitant use with certain antiarrhythmics without close monitoring
Patients with sick sinus syndrome or high-grade AV block without pacemaker
Use is contraindicated in patients with certain myocardial conditions without medical supervision
In patients with digitalis toxicity or toxicity from other cardiac glycosides
Severe electrolyte disturbances not corrected prior to digoxin administration
Acute myocarditis or acute myocardial infarction where digitalis effects are undesirable
Use contraindicated in presence of Wolff-Parkinson-White syndrome with atrial fibrillation without expert monitoring
Known ventricular tachycardia or fibrillation not controlled by other means

Drug Interactions

Amiodarone increases digoxin levels and risk of toxicity by decreasing clearance
Verapamil can increase serum digoxin concentration through reduced renal clearance
Quinidine elevates digoxin plasma levels by inhibiting P-glycoprotein
Diuretics causing hypokalemia (e.g., furosemide) increase risk of digoxin toxicity
Beta blockers may have additive negative chronotropic effects with digoxin
Cyclosporine can increase digoxin serum levels necessitating dose adjustment
Macrolide antibiotics (e.g., erythromycin) may increase digoxin absorption and levels
Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce renal clearance of digoxin
Thyroid hormone replacement can reduce digoxin levels by increasing clearance
Antacids and cholestyramine may reduce digoxin absorption when taken concomitantly
Herbal products like St. John's Wort can lower digoxin levels via P-glycoprotein induction
Calcium channel blockers interacting to alter heart rate and conduction characteristics
Antipsychotic medications may have additive effects on cardiac conduction
Caution with drugs that prolong QT interval due to increased arrhythmia risk when combined
Concurrent use with other digitalis glycosides may potentiate toxic effects

Preparations Of The Drug

Oral tablets: Lanoxin, Digitek (62.5 mcg, 125 mcg, 187.5 mcg, 250 mcg strengths)
Oral capsules: Lanoxicaps (62.5 mcg, 125 mcg, 187.5 mcg, 250 mcg)
Oral solution (elixir): commonly 0.05 mg/mL concentration for precise pediatric dosing
Injectable solution (intravenous or intramuscular): 0.25 mg/mL concentration for rapid digitalization
Available as brand name products including Digitek, Digox, Lanoxin, Lanoxicaps, and generic formulations
Dosing syringes or calibrated droppers provided for accurate measurement of liquid formulations
Unit dose packaging to ensure correct administration and minimize dosing errors
Patient-specific compounded formulations may be utilized in specialized populations
Standard packaging sizes vary according to dosage form and manufacturer
FDA-approved monographs and prescribing information accompany each form for clinical guidance
Special storage requirements to protect from moisture, heat, and light